AstraZeneca’s Fasenra (benralizumab) has been approved by the European Commission (EC) to treat eosinophilic granulomatosis ...

The launch of a new pharmaceutical product depends on a host of determinants and it just takes one factor to send the launch ...

EatMoreFruit, a UK top 10 independent healthcare communication agency, today announced the launch of its European Network to ...

LEO Pharma has shared final results from a long-term extension study of its atopic dermatitis (AD) drug Adbry ...

Merck & Co – known as MSD outside the US and Canada – has acquired Yale University oncology spinout Modifi Biosciences in a ...

Around 86% of clinical trials do not meet patient recruitment goals, ultimately failing to improve patient outcomes and ...

Knowing this, it amazes me how many pharmaceutical organisations of all sizes are missing the mark on key areas of launch ...

AstraZeneca’s (AZ) Voydeya (danicopan) has been recommended by the National Institute for Health and Care Excellence (NICE) as an add-on therapy for adults with the rare blood disorder paroxysmal ...

Merck & Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) has been recommended by the National Institute of Health and Care Excellence (NICE) to treat resectable non-small cell ...

Novartis’ Kisqali (ribociclib) has been recommended by the European Medicines Agency’s human medicines committee to reduce the risk of recurrence in early breast cancer patients. The Committee for ...

After the recent Paralympics, I can’t help but be in awe of the individuals who participated and achieved such amazing feats, despite having everyday challenges most of us can hardly comprehend. It is ...

The healthcare communications industry is in ‘re-set’ mode. Challenges with resourcing and budgets mean in-house and agency teams must work harder and more collaboratively than ever to demonstrate ...